Recent trends in management of common glomerulopathy
Diagnosis of glomerulopathy requires correlation between: (a) clinicopathological syndromes, (b) kidney histology for the abnormalities which are useful for the severity of disease, stage of activity and extent of chronicity. Subsequently, management dictates the choice of effective medications to avoid renal loss and long-term side effects. In this review article; we provide our practical experience with drug-therapy in common idiopathic and secondary glomerular diseases.
Keywords: glomerulopathy, kidney biopsy, nephrotic syndrome, Rituximab, treatment.
2- Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B. A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine 1975; 23:37–40.
3- El-Reshaid K, Amer E, Madda JP, Kapoor MM. Long-term cyclosporin A (Cy A) treatment in adults with refractory nephrotic syndrome. Renal Failure (USA) 1995; 17: 695-703.
4- Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
5- Waldman M, Austin HA. Treatment of idiopathic membranous nephropathy. JASN 2012; 23:1617-1630.
6- Kamel El-Reshaid, Hossam Eldin Tawfik Salla, Abass Ali Hakim, Raja Al-Atiyaa. Rituximab in treatment of idiopathic glomerulopathy. Saudi Journal of kidney diseases and transplantation 2012; 23:973-978.
7- Magistroni R. New development in the genetics, pathogensis, and therapy of IgA nephropathy. Kidney Int 2015; 88:974-989.
8- Strippoli GF, Manno C, Schena FP. An “evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. Am. J. Kidney Dis 2003; 41:1129–1139
9- Kumar V, Fausto N, Abbas A, eds. (2003). Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. pp: 982-983.
10- U.S. Renal Data System, USRDS 1998 Annual Data Report. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, April 1998; 23-35.
11- Rodríguez-Iturbe, B, Batsford, S. Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 2007; 71:1094–1104.
12- Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31:341-348.
13- Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosis revisited. J Am Soc Nephrol 2004; 15:241-250.
14- Kamel El-Reshaid, Wael El-Reshaid, Shaikha Al-Bader, Hossameldin Tawfik Sallam, Abbass Ali Hakim, Rajaa Al-Attiyah. New protocols for treatment of class IV lupus nephritis with emphasis on Rituximab as the sole maintenance therapy. Kuwait Medical Journal 2018; 50:343-350.
15- El-Reshaid K, Kapoor MM, El-Reshaid W, Madda JP, Varro J. The spectrum of renal disease associated with microscopic polyangiitis and classic polyarteritis nodosa in Kuwait. Nephrol Dial Transplant 1997; 12: 1874-1882.
16- Chen Y, Schieppati A, Chen X, Cai G, Zamora J, et al. (October 2014). Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. The Cochrane Database of Systemic Reviews (10): CD004293.
17- Biesenbach G, Bodlaj G, Pieringer H, Sedlak M. Clinical versus histological diagnosis of diabetic nephropathy – is renal biopsy required in type 2 diabetic patients with renal disease? QJM 2011; 104:771–774.
18- Mak SK, Gwi E, Chan KW et al. Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 1997; 12:2588–2591.
19- Nankivell BJ, PʼNg CH, OʼConnell PJ, Chapman JR. Calcineurin Inhibitor Nephrotoxicity through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. Transplantation 2016; 100:1723-1731.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).